98-16140. Draft Guidance for Industry on Providing Regulatory Submissions in Electronic FormatNDA's; Reopening of Comment Period  

  • [Federal Register Volume 63, Number 117 (Thursday, June 18, 1998)]
    [Notices]
    [Page 33375]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-16140]
    
    
    
    [[Page 33375]]
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket No. 97D-0381]
    
    
    Draft Guidance for Industry on Providing Regulatory Submissions 
    in Electronic Format--NDA's; Reopening of Comment Period
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice; reopening of comment period.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is reopening until July 
    8, 1998, the comment period for a notice announcing the availability of 
    a draft guidance for industry entitled ``Providing Regulatory 
    Submissions in Electronic Format--NDA's'' that appeared in the Federal 
    Register of April 8, 1998 (63 FR 17184). FDA is taking this action in 
    response to a request for an extension and to allow interested parties 
    additional time for review and to submit comments.
    
    DATES: Written comments by July 8, 1998. General comments on the agency 
    guidance documents are welcome at any time.
    
    ADDRESSES: Copies of the draft guidance for industry are available on 
    the Internet at http://www.fda.gov/cder/guidance/index.htm. Submit 
    written requests for single copies of the draft guidance to the Drug 
    Information Branch (HFD-210), Center for Drug Evaluation and Research, 
    Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. 
    Send one self-addressed adhesive label to assist that office in 
    processing your requests. Submit written comments on the draft guidance 
    to the Dockets Management Branch (HFA-305), Food and Drug 
    Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
    
    FOR FURTHER INFORMATION CONTACT: Kenneth Edmunds, Center for Drug 
    Evaluation and Research (HFD-350), Food and Drug Administration, 5600 
    Fishers Lane, Rockville, MD 20857, 301-827-3276; [email protected]
    
    SUPPLEMENTARY INFORMATION: In the Federal Register of April 8, 1998 (63 
    FR 17184), FDA's Center for Drug Evaluation and Research (CDER) 
    published a notice announcing the availability of a draft guidance for 
    industry entitled ``Providing Regulatory Submissions in Electronic 
    Format--NDA's.'' The draft guidance is intended to assist applicants 
    who wish to submit new drug applications (NDA's) in electronic format. 
    Although voluntary, submissions of NDA's in electronic format should 
    reduce the amount of paperwork for applicants and the agency. The April 
    8, 1998, notice invited interested persons to submit written comments 
    on the draft guidance within 60 days.
        On April 20, 1998, FDA received a letter from Pharmaceutical 
    Research and Manufacturers of America, requesting that the agency 
    extend the comment period on the draft guidance 90 days. In addition, 
    in the Federal Register of June 1, 1998 (63 FR 29741), FDA's Center for 
    Biologics Evaluation and Research (CBER) published a draft guidance for 
    industry entitled ``Guidance for Industry: Electronic Submissions of a 
    Biologics License Application (BLA) or Product License Application 
    (PLA)/Establishment License Application (ELA) to the Center for 
    Biologics Evaluation and Research.''
        Because a number of NDA sponsors have expressed the wish to see the 
    draft guidance become final as soon as possible and because the agency 
    considers this to be a dynamic document, which will be updated in the 
    future, the agency does not believe it is necessary to extend the 
    comment period an additional 90 days. However, the agency agrees that 
    an additional period will provide time for interested parties to review 
    both CDER and CBER's guidances. Therefore, the agency is reopening the 
    comment period for an additional 30 days, until July 8, 1998.
        Interested persons may, on or before July 8, 1998, submit to the 
    Dockets Management Branch (address above) written comments on the draft 
    guidance. Two copies of any comments are to be submitted, except that 
    individuals may submit one copy. Comments are to be identified with the 
    docket number found in brackets in the heading of this document. The 
    draft guidance and received comments are available for public 
    examination in the Dockets Management Branch between 9 a.m. and 4 p.m., 
    Monday through Friday.
    
        Dated: June 9, 1998.
    William K. Hubbard,
    Associate Commissioner for Policy Coordination.
    [FR Doc. 98-16140 Filed 6-17-98; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
06/18/1998
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice; reopening of comment period.
Document Number:
98-16140
Dates:
Written comments by July 8, 1998. General comments on the agency guidance documents are welcome at any time.
Pages:
33375-33375 (1 pages)
Docket Numbers:
Docket No. 97D-0381
PDF File:
98-16140.pdf